| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-H52H7 | Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein |  Human | HEK293 | SDS-PAGE | $290.00 25ug |   | ||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-H82E9 | Biotinylated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | | ||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-H52E6 | Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | | ||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-HP2H6 | PE-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein | Human | HEK293 | $410.00 25ug | | |||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | Alexa Fluor™ 488-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer) | Human | HEK293 | SDS-PAGE | $360.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | Details |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | Details |
